OBJECTIVES: We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Malawi, Zimbabwe, India, and Thailand who participated in a safety and acceptability study of BufferGel, a vaginal microbicide to determine the across-country acceptability of vaginal microbicides among women and their partners. METHODS: Quantitative survey data were collected at 7 and 14 days after use among enrolled women, and exit interviews were conducted with women and their partners in separate focus group discussions. RESULTS: Acceptability was high in all sites (73% of women approved of the microbicide). Women in Africa, where HIV infection rates are highest, were virtually unanimous in their desire for such a product, suggesting that an individual's perception of being at risk for HIV will outweigh concerns about side effects, problems applying a product, or other factors, when products are shown to be efficacious. But men and women reported that use, which was kept secret from an intimate partner, would be difficult and might "break the trust" of a relationship. CONCLUSIONS: Acceptability research across diverse settings through all stages of microbicide research, development, and post-licensure dissemination can help maximize acceptability and use.
OBJECTIVES: We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Malawi, Zimbabwe, India, and Thailand who participated in a safety and acceptability study of BufferGel, a vaginal microbicide to determine the across-country acceptability of vaginal microbicides among women and their partners. METHODS: Quantitative survey data were collected at 7 and 14 days after use among enrolled women, and exit interviews were conducted with women and their partners in separate focus group discussions. RESULTS: Acceptability was high in all sites (73% of women approved of the microbicide). Women in Africa, where HIV infection rates are highest, were virtually unanimous in their desire for such a product, suggesting that an individual's perception of being at risk for HIV will outweigh concerns about side effects, problems applying a product, or other factors, when products are shown to be efficacious. But men and women reported that use, which was kept secret from an intimate partner, would be difficult and might "break the trust" of a relationship. CONCLUSIONS: Acceptability research across diverse settings through all stages of microbicide research, development, and post-licensure dissemination can help maximize acceptability and use.
Authors: T M Hammett; G D Norton; T H Mason; S Langenbahn; K H Mayer; R R Robles; R Feudo; G R Seage Journal: J Womens Health Gend Based Med Date: 2000-12
Authors: C Coggins; K Blanchard; F Alvarez; V Brache; E Weisberg; P H Kilmarx; M Lacarra; R Massai; D Mishell; A Salvatierra; P Witwatwongwana; C Elias; C Ellertson Journal: Sex Transm Infect Date: 2000-12 Impact factor: 3.519
Authors: T M Hammett; T H Mason; C L Joanis; S E Foster; P Harmon; R R Robles; H A Finlinson; R Feudo; S Vining-Bethea; G Jeter; K H Mayer; P Doherty-Iddings; G R Seage Journal: Sex Transm Dis Date: 2000-02 Impact factor: 2.830
Authors: Martha W Moon; Gertrude N Khumalo-Sakutukwa; Judith E Heiman; Michael T Mbizvo; Nancy S Padian Journal: J Transcult Nurs Date: 2002-01 Impact factor: 1.959
Authors: K H Mayer; J Peipert; T Fleming; A Fullem; T Moench; S Cu-Uvin; M Bentley; M Chesney; Z Rosenberg Journal: Clin Infect Dis Date: 2001-01-26 Impact factor: 9.079
Authors: J van De Wijgert; A Fullem; C Kelly; S Mehendale; S Rugpao; N Kumwenda; Z Chirenje; S Joshi; T Taha; N Padian; R Bollinger; K Nelson Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Nicolette A Louissaint; Edward J Fuchs; Rahul P Bakshi; Sridhar Nimmagadda; Yong Du; Katarzyna J Macura; Karen E King; Richard Wahl; Arthur J Goldsmith; Brian Caffo; Ying Jun Cao; Jean Anderson; Craig W Hendrix Journal: J Infect Dis Date: 2012-01-25 Impact factor: 5.226
Authors: Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Sara Vargas; Candelaria Barroso; Anna L Christensen; Cynthia Woodsong; Lawrence Severy Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Billie Jo Wood; Patricia Rizzo-Price; Jeff Holden; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2007-12-05 Impact factor: 5.948
Authors: Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Sara Vargas; Julia G Shaw; E Milu Kojic; Patrick F Kiser; David R Friend; David F Katz Journal: AIDS Res Hum Retroviruses Date: 2013-12-09 Impact factor: 2.205
Authors: Toral Zaveri; Cordelia A Running; Lahari Surapaneni; Gregory R Ziegler; John E Hayes Journal: Drug Deliv Transl Res Date: 2016-10 Impact factor: 4.617